Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cancer patients with penicillin allergy may get safer antibiotics

NCT ID NCT07133074

Recruiting now Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether we can safely remove the "beta-lactam allergy" label from blood cancer patients who are not truly allergic. By doing so, doctors can use more effective antibiotics. The study will enroll 3,800 hospitalized adults with blood cancers and a reported allergy to penicillin or similar drugs. The goal is to improve antibiotic use and shorten hospital stays.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA LACTAM ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

drug allergy hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BETA LACTAM ALLERGY HEMATOLOGIC MALIGNANCY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.